Sionna Therapeutics (NASDAQ:SION) CEO Michael Cloonan Sells 10,425 Shares

Key Points

• CEO Michael Cloonan of Sionna Therapeutics sold 10,425 shares at $31.51, totaling approximately $328,491.75, reducing his ownership by 1.87%.
• Recent stock performance showed Sionna Therapeutics shares traded down $0.79 to $31.93 with a 12-month high of $34.00.
• Analyst ratings varied, with one strong buy and one sell rating, leading to an average rating of "Moderate Buy" and a consensus price target of $38.00.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) CEO Michael Cloonan sold 10,425 shares of the company's stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $31.51, for a total value of $328,491.75. Following the completion of the transaction, the chief executive officer directly owned 547,343 shares of the company's stock, valued at $17,246,777.93. This trade represents a 1.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Cloonan also recently made the following trade(s):

• On Wednesday, October 15th, Michael Cloonan sold 14,775 shares of Sionna Therapeutics stock. The shares were sold at an average price of $31.11, for a total value of $459,650.25.
• On Monday, September 29th, Michael Cloonan sold 7,793 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.70, for a total value of $231,452.10.
• On Friday, September 26th, Michael Cloonan sold 17,207 shares of Sionna Therapeutics stock. The stock was sold at an average price of $28.85, for a total value of $496,421.95.
• On Tuesday, August 26th, Michael Cloonan sold 17,574 shares of Sionna Therapeutics stock. The stock was sold at an average price of $24.96, for a total value of $438,647.04.
• On Wednesday, August 27th, Michael Cloonan sold 7,426 shares of Sionna Therapeutics stock. The shares were sold at an average price of $25.01, for a total transaction of $185,724.26.

Sionna Therapeutics Stock Performance

Shares of SION traded down $0.79 during mid-day trading on Friday, reaching $31.93. 277,728 shares of the company's stock traded hands, compared to its average volume of 215,860. The business's 50-day moving average price is $25.23 and its 200-day moving average price is $18.36. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $34.00.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.27.

Institutional Investors Weigh In On Sionna Therapeutics

Several institutional investors have recently bought and sold shares of SION. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics in the second quarter worth $31,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Sionna Therapeutics during the 2nd quarter valued at $45,000. The Manufacturers Life Insurance Company increased its holdings in Sionna Therapeutics by 13.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,038 shares of the company's stock worth $660,000 after acquiring an additional 4,489 shares during the period. Virtus Investment Advisers LLC purchased a new position in Sionna Therapeutics during the second quarter worth about $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Sionna Therapeutics during the second quarter valued at approximately $117,000.

Analyst Ratings Changes

A number of analysts recently weighed in on SION shares. Weiss Ratings reiterated a "sell (d)" rating on shares of Sionna Therapeutics in a research report on Wednesday, October 8th. Raymond James Financial began coverage on shares of Sionna Therapeutics in a research report on Tuesday, September 2nd. They issued a "strong-buy" rating and a $45.00 price objective for the company. Royal Bank Of Canada assumed coverage on Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 price target for the company. Wall Street Zen upgraded shares of Sionna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Finally, Jones Trading began coverage on shares of Sionna Therapeutics in a research report on Monday, September 8th. They set a "buy" rating and a $46.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Sionna Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $38.00.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.